Publications
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine
- Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry2022 | Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Siponimod in the treatment of secondary - progressive multiple sclerosis - case report2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS2021 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Treatment persistence to ocrelizumab and local experience2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
Loading network view...